Genfleet Therapeutics (shanghai) Inc.
Clinical trials sponsored by Genfleet Therapeutics (shanghai) Inc., explained in plain language.
-
New targeted drug takes on hard-to-treat pancreatic cancer
Disease control Not yet recruitingThis study tests a new drug, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). Participants must have already tried at least one prior treatment. The goal is to see if GFH375 helps people live longe…
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests a new drug called GFH276 in people with advanced cancers that have a specific gene change (RAS mutation). The cancers include pancreatic, lung, and colorectal cancer. The goal is to find a safe dose and see if the drug can shrink tumors. About 450 adults aged 18-…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for hard-to-treat lung cancer: targeted drug combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called GFH375, alone or with other medicines, in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. About 90 participants will be split into three groups to see which treatment works best. The goal is to shrink tumo…
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC